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Abstract
Objective: The aim of this study was to identify prognostic factors, particularly pathological variables,
that influence disease-free and overall survival following resection for colorectal liver metastases (CRLM).
Methods: Patients undergoing CRLM resection from January 2005 to December 2011 were included.
Data analysed included information on demographics, laboratory results, operative findings,
histopathological features and survival.
Results: A total of 259 patients were included. Of these, 138 (53.3%) patients developed recurrent
disease, of which 95 died. The median length of follow-up in the remaining patients was 28 months
(range: 12–96 months). There were significant associations between recurrence and higher tumour
number (P = 0.002), presence of perineural invasion (P = 0.009) and positive margin (R1) resection (P =
0.002). Multivariate analysis showed all three prognostic factors to be independent predictors of disease-
free survival. Significantly poorer overall survival after hepatic resection for CRLM was observed in
patients undergoing hemi-hepatectomy or more radical resection (P = 0.021), patients with a higher
number of tumours (P = 0.024) and patients with perineural invasion (P < 0.001). Multivariate analysis
showed perineural invasion to be the only independent predictor of overall survival.
Conclusions: The presence of perineural invasion, multiple tumours and an R1 margin were associated
with recurrent disease. Perineural invasion was also an independent prognostic factor with respect to
overall survival.
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Introduction
Hepatic resection has become the treatment of choice in
resectable colorectal liver metastases (CRLM) and is associated
with longterm survival in these patients. Around 25% of patients
have synchronous liver metastases at presentation and a further
20% subsequently develop metachronous liver disease, usually
within 2 years of the resection of the primary tumour.1,2 Despite
the variability in the selection criteria of patients with CRLM for
hepatic resection, 5-year survival rates of up to 58% have been
reported.1,3,4
Several clinicopathological features have been identified as
prognostic factors. These include the size of the largest hepatic
metastasis, the number of hepatic metastases, the distribution of
hepatic tumours, the extent of hepatic resection, preoperative
expression of C-reactive protein (CRP) and neutrophil-to-
lymphocyte ratio (NLR), and the status of the resection margin.5–9
Various hepatobiliary units have proposed prognostic scoring
systems to stratify patients into risk categories for clinical man-
agement.5,10 In patients with primary liver tumours such as those
of cholangiocarcinoma and hepatocellular carcinoma, lymphatic,
vascular and perineural invasion are well-established pathological
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variables that influence overall survival following hepatic
resection.11–13 To date, data on the prognostic implications of vas-
cular, biliary, perineural and lymphatic invasion in patients with
CRLM are limited. In addition to clinical scoring systems, these
histopathological features may potentially be useful in selecting
patients for adjuvant therapy and clinical trials.
The aim of the current study was to analyse the impact of
pathological variables, in particular biliary, vascular, perineural
and lymphatic invasion, on outcomes in patients after potentially
curative hepatic resection for CRLM.
Materials and methods
Patients
Patients with CRLM undergoing hepatic resection at Nottingham
University Hospitals National Health Service (NHS) Trust, Not-
tingham, UK, during the 7-year period from January 2005 to
December 2011 were identified from a prospectively maintained
database. All patients who underwent primary hepatic resection
with curative intent were included in the analysis. Prior to
any treatment, patients were discussed at a specialist multidisci-
plinary (MDT) meeting that included hepatobiliary surgeons,
hepatologists, oncologists, radiologists and pathologists. Preop-
erative radiological assessment included a computed tomography
(CT) scans of the thorax, abdomen and pelvis and magnetic
resonance imaging (MRI) of the liver. Patients considered for
neoadjuvant chemotherapy and patients with indeterminate
lesions, in particular lung nodules, underwent positron emission
tomography (PET).
A subgroup of patients were given neoadjuvant oxaliplatin-
based chemotherapy prior to liver resection. If this was unsuitable,
an irinotecan-based regimen was administered. Following this,
patients underwent reassessment prior to resection. According to
the unit’s protocol, all patients were offered adjuvant chemo-
therapy following liver resection unless they had undergone
chemotherapy adjuvant to bowel resection within 12 months of
the primary hepatic resection.
Collated data included information on patient demographics,
laboratory analyses, type of surgical resection, histopathology
analysis and clinical outcomes.
Surgery
Parenchymal transection was performed using the Cavi-Pulse
Ultrasonic Surgical Aspirator (CUSA). Intraoperative ultrasound
was performed to confirm the findings of preoperative imaging
and to assist in surgical planning. The number of hepatic
(Couinaud14) segments resected was determined by the procedure
to be performed according to the Brisbane nomenclature.15 The
type of surgical procedure was selected with the aim of achieving
the resection of all macroscopic disease, clear resection margins
and the preservation of sufficient remnant liver. The extent of
hepatic resection was used to classify study patients into two
groups according to whether the resection represented a lesser
procedure than hemi-hepatectomy, or a hemi-hepatectomy or
more radical resection.
Follow-up
Patients were followed up in specialist hepatobiliary clinics. Fol-
lowing the initial postoperative review at 1 month, all patients
were examined in the outpatient clinic at 3, 6, 12, 18 and
24 months and annually thereafter. At each clinical review,
carcinoembryonic antigen (CEA) levels were measured. All
patients in this study underwent a minimum follow-up of 1 year
following hepatic resection for CRLM.
Surveillance imaging included CT of the thorax, abdomen and
pelvis. Patients underwent 6-monthly CT scans during the first
2 years postoperatively, followed by annual CT scans thereafter.
Liver MRI was used to characterize suspicious hepatic lesions
demonstrated on CT. The development of symptoms suspicious
of recurrence at any time-point prompted an earlier than sched-
uled review.
Following the detection of recurrence on surveillance imaging,
patients with unresectable disease were referred to the oncologist
and patients who were suitable for further surgery were submitted
to liver and/or lung resection within an average of 4 weeks.Overall
and disease-free survival data were recorded; disease-free survival
was defined as the time from primary hepatic resection to the first
documented disease recurrence on imaging. Overall survival was
defined as the time between the dates of primary hepatic resection
and death or most recent follow-up if the patient was still alive.
Histopathological analysis
Histopathological data for the resected liver specimen were col-
lated. These included: tumour size (maximum diameter); tumour
number, and the status of the resection margin. A negative margin
(R0) resection was defined by no microscopic evidence of tumour
at or within 1 mm of the margin. In addition, lymphatic,
perineural, biliary and vascular invasion were determined in
haematoxylin and eosin (H&E)-stained sections (Fig. 1).
Biliary invasion was defined by the presence of adenocarcinoma
cells infiltrating through part of or completely replacing the bile
duct epithelium in the large, medium-sized or small intrahepatic
bile ducts (Fig. 1b–d). Perineural invasion was defined as tumour
cells within any layer of the nerve sheath or tumour in the
perineural space (Fig. 1d). Lymphatic invasion was defined by the
presence of adenocarcinoma cells within the lumen of the lym-
phatic space (Fig. 1e). The presence of vascular invasion was
defined by adenocarcinoma cells within the lumen of the vascular
channel (Fig. 1f).
In this study, all histopathological parameters in hepatic resec-
tion specimens of CRLM were reviewed by a specialist
hepatobiliary histopathologist (AMZ).
Statistical analysis
Categorical data were presented as frequencies and proportions
(%). The median and range were used to describe continuous
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Figure 1 (a) Gross specimen of hepatic resection showing a single tumour nodule. The distance between the front of the tumour and themargin
of excision is marked with an arrowhead. Histopathology shows: (b) early invasion of the biliary epithelium by metastatic adenocarcinoma; (c)
invasion of the biliary epithelium of a medium-sized duct by metastatic adenocarcinoma (arrowhead); (d) complete replacement of the biliary
epithelium by adenocarcinoma (black arrowhead) with perineural invasion (red arrowhead) and adenocarcinoma cells within vascular spaces
(green arrowhead); (e) multiple lymphatic spaces containing metastatic adenocarcinoma cells (green arrowheads), and (f) metastatic
adenocarcinoma within the lumen of a blood vessel (top right). [Haematoxylin and eosin stain; original magnification (b) ×20, (c) ×20, (d) ×10,
(e) ×10, (f) ×10]
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data. Categorical data were analysed using Pearson’s chi-squared
test. The Kaplan–Meier method was used to assess actuarial and
disease-free survival. Univariate analysis was performed to assess
for any significant difference in clinicopathological characteristics
that influenced disease recurrence and survival following hepatic
resection. Multivariate analysis was performed using Cox regres-
sion (stepwise forward model) for variables significant on
univariate analysis. Statistical analyses were performed using spss
for Windows Version 16.0 (SPSS, Inc., Chicago, IL, USA). Statis-
tical significance was set at the 5% level.
Results
Patient demographics, surgical procedures and
pathological data
During the study period, 261 patients underwent primary hepatic
resection for CRLM. Two patients died postoperatively. Data for
these two patients were removed from further analyses. Eleven
patients underwent induction chemotherapy prior to liver resec-
tion. Two patients submitted to staged liver resections and three
patients underwent portal vein embolization. A total of 138
(53.3%) patients developed recurrent disease; 95 of these patients
died. The median length of follow-up in the remaining patients
was 28 months (range: 12–96 months).
Prognostic factors influencing disease recurrence and
overall survival
Multivariate analysis identified three independent predictors of
disease-free survival (Table 1): tumour number; perineural inva-
sion, and resection margin. The presence of perineural invasion
was the only independent predictor of poorer overall survival on
multivariate analysis (Table 2).
Impact of perineural invasion on survival
Patients with perineural invasion were found to have a signifi-
cantly higher likelihood of lymphatic (P < 0.001), vascular (P =
0.003) or biliary (P < 0.001) invasion compared with patients
who did not exhibit perineural invasion (Table 3). Patients with
perineural invasion were more likely to undergo a hemi-
hepatectomy or more radical resection (P = 0.029).
Median disease-free and overall survival in patients with
perineural invasion were 12 months and 21 months, respectively.
Five-year disease-free survival in patients without perineural inva-
sion was 43.1% (P = 0.009) (Fig. 2). Five-year overall survival in
patients without perineural invasion was 48.0% (P < 0.001)
(Fig. 3). None of the patients with perineural invasion survived to
5 years.
Discussion
Hepatic resection for CRLM has consistently achieved good
longterm disease-free and overall survival based on absence of
recurrence16,17 and thus offers outcomes that stand in stark
contrast to those in patients with unresectable disease.18 The
present series demonstrates that tumour number, resection
margin and perineural invasion significantly influenced outcome.
Number of metastases
Various studies have shown tumour number to significantly
influence survival outcomes,7,8,19 although other authors have
not demonstrated this finding.1,5,7,20 In the present series, patients
with multiple metastases had poorer disease-free survival, but
this variable did not influence overall survival. The fact that
tumour number has been inconsistently identified suggests that
other factors, such as tumour biology, may influence outcomes
in CRLM patients depending on their tumour burden at
presentation.
Resection margin
Some authors have observed that resection margin and margin
width did not correlate significantly with survival following
resection for CRLM,21 whereas others have shown margin status
to be a predictor of survival outcome.22,23 A recent meta-analysis24
demonstrated that a margin of ≥ 1 cm confers a survival benefit
compared with a margin of < 1 cm. In the present cohort,
tumour at the resection margin was a predictor of poorer
disease-free survival, but not overall survival. These differences
suggest that only a selected group of CRLM patients undergoing
resection are influenced by an R0 margin, especially in the era of
systemic chemotherapy, which represents an important avenue of
treatment in the multimodal approach to therapy in these
patients.25–27
Intrahepatic invasion
Few studies have investigated the incidence of intrahepatic
invasion,28–34 and the exact definitions, types and methods of
detection in CRLM specimens have not been described. Sasaki
et al.32 defined portal vein, hepatic vein and bile duct invasion as
cancer cells invading the lumen of an artery or vein or bile duct
branches within the liver, and lymphatic invasion as cancer cells
involving the luminal structures in the portal area lined by
endothelial cells. Korita et al.34 defined lymphatic invasion as
the presence of tumour cells within vessels that showed
immunoreactivity for D2-40 monoclonal antibody, but did not
define other forms of intrahepatic invasion. By contrast, the
present study defined vascular, biliary, lymphatic and perineural
invasion, as well as the methods used to detect the presence of
tumour cells in their respective channels.
A limited number of studies have assessed the influence of
vascular invasion on outcomes in patients with CRLM.27,29–31,34
Although improved survival has been observed in patients
without portal vein invasion compared with patients with portal
vein invasion,35 the sample sizes referred to elsewhere were small,
leading to significant heterogeneity.27,29,31,32 Similarly, few studies
have reported outcomes in patients with hepatic vein invasion in
CRLM specimens,29,31,32 the influence of which remains to be
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determined.35 A recent meta-analysis of five studies that assessed
outcomes in CRLM patients with biliary invasion29,31–33,36 showed
no correlation between the presence of biliary invasion and overall
survival.35 A meta-analysis of two studies evaluating the impact of
lymphatic invasion on outcomes in CRLM patients32,34 demon-
strated lymphatic invasion to be associated with significantly
poorer survival.35 In the present study, vascular, lymphatic and
biliary invasion in CRLM patients did not significantly influence
survival outcome. Similarly, Bockhorn et al.37 observed that the
presence of vascular invasion or lymphatic infiltration in isolation
did not significantly influence survival, but the presence of both in
combination resulted in significantly poorer survival than in
patients without vascular and lymphatic invasion.
Perineural invasion
Leibig et al.38 showed perineural infiltration to be a predictor of
survival in patients undergoing surgery for colorectal cancer.
Although perineural invasion has been observed in 12–17% of
Table 1 Statistical analysis of prognostic factors with respect to disease-free survival
Demographic, clinical and
pathological factors
Survival, months,
median (range)
Univariate
analysis
Multivariate
analysis
Risk ratio
(95% CI)
Demographic factors 0.059
Age
<65 years (n = 82) 14 (3–82)
≥65 years (n = 177) 18 (3–96)
Gender 0.771
Male (n = 166) 18 (3–96)
Female (n = 93) 15 (3–84)
Presentation 0.704
Synchronous (n = 105) 18 (3–79)
Metachronous (n = 154) 16 (3–96)
Extent of surgery
Less than hemi-hepatectomy (n = 136) 18 (3–84) 0.336
Hemi-hepatectomy or more (n = 123) 15 (3–96)
Pathological factors
Largest tumour size 0.110
<5 cm (n = 173) 18 (3–84)
≥5 cm (n = 86) 14 (3–96)
Number of metastases 0.002 0.018 0.655 (0.461–0.930)
Solitary (n = 127) 21 (3–96)
Multiple (n = 132) 12 (3–84)
Lymphatic invasion 0.942
Positive (n = 42) 14 (3–96)
Negative (n = 217) 17 (3–84)
Vascular invasion 0.441
Positive (n = 115) 15 (3–96)
Negative (n = 144) 18 (3–84)
Perineural invasion 0.009 0.007 2.346 (1.256–4.382)
Positive (n = 13) 6 (3–52)
Negative (n = 246) 18 (3–96)
Biliary invasion 0.451
Positive (n = 94) 18 (3–96)
Negative (n = 165) 16 (3–84)
Resection margin (R0) 0.002 0.018 0.618 (0.414–0.922)
R0 (n = 205) 18 (3–96)
R1 (n = 54) 10 (3–69)
95% CI, 95% confidence interval
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patients undergoing hepatic resection for CRLM,28,29,33 it has been
reported not to significantly influence survival.28,33 In the present
cohort, 5% of patients had perineural invasion and achieved sig-
nificantly poorer disease-free and overall survival. In addition, the
presence of perineural invasion was significantly associated with
lymphatic, vascular and biliary invasion. These results demon-
strate that this subgroup of patients is more likely to have aggres-
sive tumour biology resulting in intrahepatic invasion of the
tumour. This may account for the significantly higher number of
major liver resections required to achieve clear margins in this
group of patients.
Although it was retrospective in nature, the present study
defined each histopathological feature of intrahepatic invasion
and the methods used for its detection. The presence of perineural
invasion following resection of CRLM was an independent pre-
dictor of a poorer outcome. The association of perineural invasion
with other features of intrahepatic invasion is likely to reflect more
aggressive disease and hence a poorer outcome.
Table 2 Statistical analysis of prognostic factors with respect to overall survival
Demographic, clinical and
pathological factors
Survival, months,
median (range)
Univariate
analysis
Multivariate
analysis
Risk ratio
(95% CI)
Demographic factors 0.718
Age
<65 years (n = 82) 24 (5–82)
≥65 years (n = 177) 27 (4–96)
Gender 0.709
Male (n = 166) 25 (4–96)
Female (n = 93) 27 (4–84)
Presentation 0.964
Synchronous (n = 105) 28 (7–79)
Metachronous (n = 154) 25 (4–96)
Extent of surgery
Less than hemi-hepatectomy (n = 136) 24 (7–84) 0.021 0.119 1.410 (0.916–2.170)
Hemi-hepatectomy or more (n = 123) 27 (4–96)
Pathological factors
Largest tumour size 0.263
<5 cm (n = 173) 27 (9–84)
≥5 cm (n = 86) 24 (4–96)
Number of metastases 0.024 0.103 0.705 (0.463–1.073)
Solitary (n = 127) 27 (4–96)
Multiple (n = 132) 25 (6–84)
Lymphatic invasion 0.730
Positive (n = 42) 24 (4–96)
Negative (n = 217) 25 (4–84)
Vascular invasion 0.612
Positive (n = 115) 24 (4–96)
Negative (n = 144) 28 (5–84)
Perineural invasion <0.001 <0.001 3.152 (1.636–6.074)
Positive (n = 13) 19 (6–56)
Negative (n = 246) 26 (4–96)
Biliary invasion 0.901
Positive (n = 94) 24 (4–96)
Negative (n = 165) 26 (4–84)
Resection margin (R0) 0.087
R0 (n = 205) 27 (4–96)
R1 (n = 54) 20 (4–69)
95% CI, 95% confidence interval
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Table 3 Demographic, clinical and pathological factors in patients with and without perineural invasion
Demographic, clinical and
pathological factors
Patients with perineural
invasion (n = 13), n
Patients without
perineural invasion
(n = 246), n
P-value
Demographic factors
Age ≥65 years 6 171 0.078
Male gender 9 157 0.692
Synchronous presentation 3 102 0.188
Extent of surgery
Hemi-hepatectomy or more 10 113 0.029
Pathological factors
Largest tumour size ≥5 cm 7 79 0.105
Solitary hepatic metastases 4 123 0.172
Lymphatic invasion 7 35 <0.001
Vascular invasion 11 104 0.003
Biliary invasion 11 83 <0.001
Resection margin 12 193 0.231
1.0
0.8
0.6
0.4
0.2
0.0
0 12 24
Time, months
D
is
ea
se
-f
re
e 
su
rv
iv
al
 (
pr
op
or
tio
n)
36
P = 0.009
No perineural invasion
Perineural invasion
Numbers at risk
Time, months 0 12 36
Patients with perineural 
invasion (n = 13) 
13 7 1
Patients without perineural 
invasion (n = 246)
246 175 51
Figure 2 Disease-free survival in patients with and without perineural invasion
842 HPB
HPB 2014, 16, 836–844 © 2014 International Hepato-Pancreato-Biliary Association
Conflicts of interest
None declared.
References
1. Dexiang Z, Li R, Ye W, Haifu W, Yunshi Z, Qinghai Y et al. (2012) Outcome
of patients with colorectal liver metastasis: analysis of 1613 consecutive
cases. Ann Surg Oncol 19:2860–2868.
2. Bockhorn M, Frilling A, Fruhauf NR, Neuhaus J, Molmenti E, Trarbach T
et al. (2008) Survival of patients with synchronous and metachronous
colorectal liver metastases – is there a difference? J Gastrointest Surg
12:1399–1405.
3. Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg
SM. (2004) Five-year survival after resection of hepatic metastases from
colorectal cancer in patients screened by positron emission tomography
with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 240:438–447; dis-
cussion 447–450.
4. Gomez D, Sangha VK, Morris-Stiff G, Malik HZ, Guthrie AJ, Toogood GJ
et al. (2010) Outcomes of intensive surveillance after resection of hepatic
colorectal metastases. Br J Surg 97:1552–1560.
5. Rees M, Tekkis PP, Welsh FK, O'Rourke T, John TG. (2008) Evaluation of
longterm survival after hepatic resection for metastatic colorectal cancer:
a multifactorial model of 929 patients. Ann Surg 247:125–135.
6. Wong VK,Malik HZ, Hamady ZZ, Al-Mukhtar A, Gomez D, Prasad KR et al.
(2007) C-reactive protein as a predictor of prognosis following curative
resection for colorectal liver metastases. Br J Cancer 96:222–225.
7. Konopke R, Kersting S, Distler M, Dietrich J, Gastmeier J, Heller A et al.
(2009) Prognostic factors and evaluation of a clinical score for predicting
survival after resection of colorectal liver metastases. Liver Int 29:89–102.
8. Malik HZ, Gomez D, Wong V, Al-Mukthar A, Toogood GJ, Lodge JP et al.
(2007) Predictors of early disease recurrence following hepatic resection
for colorectal cancer metastasis. Eur J Surg Oncol 33:1003–1009.
9. Are C, Gonen M, Zazzali K, Dematteo RP, Jarnagin WR, Fong Y et al.
(2007) The impact of margins on outcome after hepatic resection for
colorectal metastasis. Ann Surg 246:295–300.
10. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. (1999) Clinical
score for predicting recurrence after hepatic resection for metastatic
colorectal cancer: analysis of 1001 consecutive cases. Ann Surg
230:309–318; discussion 318–321.
11. Gomez D, Farid S, Malik HZ, Young AL, Toogood GJ, Lodge JP et al.
(2008) Preoperative neutrophil-to-lymphocyte ratio as a prognostic pre-
dictor after curative resection for hepatocellular carcinoma.World J Surg
32:1757–1762.
12. Uenishi T, Hirohashi K, Kubo S, Yamamoto T, Yamazaki O, Kinoshita H.
(2001) Clinicopathological factors predicting outcome after resection of
mass-forming intrahepatic cholangiocarcinoma. Br J Surg 88:969–974.
13. Kawarada Y, Yamagiwa K, Das BC. (2002) Analysis of the relationships
between clinicopathologic factors and survival time in intrahepatic
cholangiocarcinoma. Am J Surg 183:679–685.
14. Couinaud C. (1954) Anatomic principles of left and right regulated hepa-
tectomy: technics. Presse Med 62:709–712.
1.0
0.8
0.6
0.4
0.2
0.0
0 12 24
Time, months
O
ve
ra
ll 
su
rv
iv
al
 (
pr
op
or
tio
n)
36
P < 0.001
No perineural invasion
Perineural invasion
Numbers at risk
Time, months 0 12 36
Patients with perineural
invasion (n = 13)
13 11 1
Patients without perineural 
invasion (n = 246)
246 231 82
Figure 3 Overall survival in patients with and without perineural invasion
HPB 843
HPB 2014, 16, 836–844 © 2014 International Hepato-Pancreato-Biliary Association
15. Strasberg SM. (2005) Nomenclature of hepatic anatomy and resections:
a review of the Brisbane 2000 system. J Hepatobiliary Pancreat Surg
12:351–355.
16. Jaeck D, Bachellier P, Guiguet M, Boudjema K, Vaillant JC, Balladur P
et al. (1997) Longterm survival following resection of colorectal hepatic
metastases. Association Française de Chirurgie. Br J Surg 84:977–980.
17. Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M
et al. (2007) Actual 10-year survival after resection of colorectal liver
metastases defines cure. J Clin Oncol 25:4575–4580.
18. Scheele J, Stangl R, Altendorf-Hofmann A. (1990) Hepatic metastases
from colorectal carcinoma: impact of surgical resection on the natural
history. Br J Surg 77:1241–1246.
19. Schindl M, Wigmore SJ, Currie EJ, Laengle F, Garden OJ. (2005) Prog-
nostic scoring in colorectal cancer liver metastases: development and
validation. Arch Surg 140:183–189.
20. Lee WS, Kim MJ, Yun SH, Chun HK, Lee WY, Kim SJ et al. (2008) Risk
factor stratification after simultaneous liver and colorectal resection for
synchronous colorectal metastasis. Langenbecks Arch Surg 393:13–19.
21. Bodingbauer M, Tamandl D, Schmid K, Plank C, Schima W, Gruenberger
T. (2007) Size of surgical margin does not influence recurrence rates after
curative liver resection for colorectal cancer liver metastases. Br J Surg
94:1133–1138.
22. Hamady ZZ, Cameron IC, Wyatt J, Prasad RK, Toogood GJ, Lodge JP.
(2006) Resection margin in patients undergoing hepatectomy for
colorectal liver metastasis: a critical appraisal of the 1 cm rule. Eur J Surg
Oncol 32:557–563.
23. Gomez D, Morris-Stiff G, Toogood GJ, Lodge JP, Prasad KR. (2010)
Interaction of tumour biology and tumour burden in determining outcome
after hepatic resection for colorectal metastases. HPB 12:84–93.
24. Dhir M, Lyden ER, Wang A, Smith LM, Ullrich F, Are C. (2011) Influence of
margins on overall survival after hepatic resection for colorectal metas-
tasis: a meta-analysis. Ann Surg 254:234–242.
25. de Haas RJ, Wicherts DA, Flores E, Azoulay D, Castaing D, Adam R.
(2008) R1 resection by necessity for colorectal liver metastases: is it still
a contraindication to surgery? Ann Surg 248:626–637.
26. Ayez N, Lalmahomed ZS, Eggermont AM, Ijzermans JN, de Jonge J, van
Montfort K et al. (2012) Outcome of microscopic incomplete resection
(R1) of colorectal liver metastases in the era of neoadjuvant chemo-
therapy. Ann Surg Oncol 19:1618–1627.
27. Hayashi M, Inoue Y, Komeda K, Shimizu T, Asakuma M, Hirokawa F et al.
(2011) Clinicopathological analysis of recurrence patterns and prognostic
factors for survival after hepatectomy for colorectal liver metastasis. BMC
Surg 10:27.
28. Yamamoto J, Sugihara K, Kosuge T, Takayama T, Shimada K,
Yamasaki S et al. (1995) Pathologic support for limited hepatectomy in
the treatment of liver metastases from colorectal cancer. Ann Surg
221:74–78.
29. Yamamoto J, Shimada K, Kosuge T, Yamasaki S, Sakamoto M, Fukuda
H. (1999) Factors influencing survival of patients undergoing hepatec-
tomy for colorectal metastases. Br J Surg 86:332–337.
30. Tanaka K, Shimada H, Kubota K, Ueda M, Endo I, Sekido H et al. (2005)
Effectiveness of prehepatectomy intra-arterial chemotherapy for multiple
bilobar colorectal cancer metastases to the liver: a clinicopathologic
study of peritumoral vasculobiliary invasion. Surgery 137:156–164.
31. Shirabe K, Takenaka K, Gion T, Fujiwara Y, Shimada M, Yanaga K et al.
(1997) Analysis of prognostic risk factors in hepatic resection for meta-
static colorectal carcinoma with special reference to the surgical margin.
Br J Surg 84:1077–1080.
32. Sasaki A, Aramaki M, Kawano K, Yasuda K, Inomata M, Kitano S. (2002)
Prognostic significance of intrahepatic lymphatic invasion in patients with
hepatic resection due to metastases from colorectal carcinoma. Cancer
95:105–111.
33. Okano K, Yamamoto J, Moriya Y, Akasu T, Kosuge T, Sakamoto M et al.
(1999) Macroscopic intrabiliary growth of liver metastases from colorectal
cancer. Surgery 126:829–834.
34. Korita PV, Wakai T, Shirai Y, Sakata J, Takizawa K, Cruz PV et al. (2007)
Intrahepatic lymphatic invasion independently predicts poor survival and
recurrences after hepatectomy in patients with colorectal carcinoma liver
metastases. Ann Surg Oncol 14:3472–3480.
35. Knijn N, de Ridder JA, Punt CJ, de Wilt JH, Nagtegaal ID. (2013)
Histopathological evaluation of resected colorectal cancer liver metasta-
ses: what should be done? Histopathology 63:149–156.
36. Okano K, Maeba T, Moroguchi A, Ishimura K, Karasawa Y, Izuishi K et al.
(2003) Lymphocytic infiltration surrounding liver metastases from
colorectal cancer. J Surg Oncol 82:28–33.
37. Bockhorn M, Sotiropoulos G, Neuhaus J, Sgourakis G, Sheu SY,
Molmenti E et al. (2009) Prognostic impact of intrahepatic lymphatic and
microvascular involvement in cases of colorectal liver metastases. Int J
Colorectal Dis 24:845–850.
38. Liebig C, Ayala G, Wilks J, Verstovsek G, Liu H, Agarwal N et al. (2009)
Perineural invasion is an independent predictor of outcome in colorectal
cancer. J Clin Oncol 27:5131–5137.
844 HPB
HPB 2014, 16, 836–844 © 2014 International Hepato-Pancreato-Biliary Association
